PK Comparisons of Bepotastine Besilate 10 mg and Bepotastine Salicylate 9.64 mg

Inclusion Criteria: * subjects aged between 20 and 45 years * Body weight \> 50 kg (in case of female \> 45 kg) with BMI between 18 and 29 kg/m2 * Signed and dated informed consent form which meets all criteria of current FDA and KFDA regulations Exclusion Criteria: * subjects with acute conditions. * presence of history affecting ADME * Clinically significant history or current evidence of a hepatic, renal, gastrointestinal, or hematologic abnormality * Hepatitis B, hepatitis C, or HIV infection revealed on the laboratory findings * Any other acute or chronic disease * A history of hypersensitivity to bepotastine * A history of alcohol or drug abuse * Participation in another clinical trial within 2 months * smoked \>10 cigarettes daily * consumption over 5 glasses daily of beverages containing xanthine derivatives * use of any medication having the potential to affect the study results within 10 days before the start of the study. * medication of the inhibitors or inducers of DME including barbiturates within 1 month * one of abnormal lab findings as like * c. AST/ALT \> UNL (upper normal limit) x 1.5 * Total bilirubin \> UNL x 1.5